Review of major clinical trials with mycophenolate mofetil in cardiac transplantation

Transplantation

Volumn 80, Issue SUPPL. 2, 2005, Pages

  Kobashigawa, Jon A ^a,c   Meiser, Bruno M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitor; Cardiac transplantation; Mycophenolate mofetil; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STATINE DERIVATIVE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LONG TERM CARE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; CALCINEURIN; CHILD; CLINICAL TRIALS; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MYCOPHENOLIC ACID;

EID: 27644521264     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000186383.22264.b3     Document Type: Review

References (49)

1. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethyl ester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659.
2. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991; 23: 19.
3. Pethig K, Heublein B, Wahlers T, et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004; 23: 61.
4. Weigel G, Griesmacher A, Karimi A, et al. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 2002; 21: 1074.
5. Lietz K, John R, Schuster M, et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc 2002; 34: 1828.
6. Schmid C, Garritsen HS, Kelsch R, et al. Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Thorac Cardiovasc Surg 1998; 46: 161.
7. Rose ML, Smith J, Dureau G, et al. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282.
8. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
9. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75.
10. Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13: 444.
11. Taylor DO, Ensley RD, Olsen SL, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994; 13: 571.
12. Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10: 136.
13. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507.
14. Hosenpud JD, Novick RJ, Bennett LE, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirteenth Official Report-1996. J Heart Lung Transplant 1996; 15: 655.
15. Miller LW, Naftel DC, Bourge RC, et al. Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13: 381.
16. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517.
17. Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001; 72: 1662.
18. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: Which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78: 591.
19. Seebacher G, Weigel G, Griesmacher A, et al. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study. Transplant Proc 1999; 31: 3291.
20. Teebken OE, Struber M, Harringer W, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. Transplant Proc 2002; 34: 1265.
21. Taylor DO, Sharma RC, Kfoury AG, Renlund DG. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant 1999; 13: 296.
22. Angermann CE, Stork S, Costard-Jackle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients-the IMPROVED multi-centre study. Eur Heart J 2004; 25: 1626.
23. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
24. Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976.
25. Arizon del Prado JM, Aumente MD, Lopez Granados A, et al. Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study. Transplant Proc 2002; 34: 144.
26. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143.
27. Kobashigawa J, Miller LW, Felker GM, et al. 12 month report of a 3 arm multicenter comparison of tacrolimus (TAC), MMF or TAC/sirolimus (SRL) and steroids vs cyclosporine microemulsion (CyA), MMF and steroids in de novo cardiac transplant recipients. J Heart Lung Transplant 2005;24.
28. Rabago G, Mantio N, Palomo J, et al. Management of chronic nephrotoxicity induced by ciclosporine A introducing mycophenolate mofetil and decreasing ciclosporine A levels. Results of a two years multicentric study. Washington, DC: American Transplant Congress, 2002: 317.
29. Dureau G, Obadia JF, Chuzel M, Boissonnat P. Introduction of mycophenolate mofetil and cyclosporine withdrawal in heart transplant patients with progressive deteriorating renal function. Transplant Proc 2000; 32: 461.
30. Meiser B, Reichart B, Adamidis I, et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5: 827.
31. Reddy SC, Laughlin K, Webber SA. Immunosuppression in pediatric heart transplantation: 2003 and beyond. Curr Treat Options Cardiovasc Med 2003; 5: 417.
32. Boucek MM, Pietra B, Sondheimer H, et al. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum. Transplant Proc 1997; 29(Suppl): 16S.
33. Dipchand AI, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 112.
34. Groetzner J, Reichart B, Roemer U, et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. Ann Thorac Surg 2005; 79: 53.
35. Costello JM, Pahl E. Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients. Paediatr Drugs 2002; 4: 705.
36. Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005; 79: 1405.
37. Weis M, Wildhirt SM, Schulze C, et al. Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J Cardiovasc Pharmacol 2000; 36: 776.
38. Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3445.
39. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45: 1532.
40. Kobashigawa J, Tobis J, Mentzer RM, et al. Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients. J Heart Lung Transplant. 2004; 23 (Suppl): S42.
41. Barten MJ, van Gelder T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002; 2: 719.
42. Cantin B, Giannetti N, Parekh H, et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002; 16: 196.
43. Yamani MH, Starling RC, Goormastic M, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000; 69: 2326.
44. Hesse CJ, Vantrimpont P, van Riemsdijk-van Overbeeke IC, et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. Transplant Proc 2001; 33: 2163.
45. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: Does the MPA level matter? Am J Transplant 2004; 4: 1495.
46. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000; 19: 1071.
47. Dipchand AI, Pietra B, McCrindle BW, et al. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001; 20: 1035.
48. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2003; 17: 144.
49. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305.